title: Engineering antibodies for therapy.
abstract: Success in the generation of an antibody-based therapeutic requires careful consideration of the binding site, to achieve specificity and high affinity; of the effector, to produce the desired therapeutic effect; of the means of attachment of the effector to the binding site; production of the end product; and the response made by the patient to the administered compound. Each of these areas is receiving attention by antibody-engineering techniques. The number of potentially useful monoclonal antibodies developed over the last 10 years, and currently in clinical trials or preregistration, is now being increased by these engineered newcomers. It will be interesting to see over the next few years how many of these antibodies, and of which kind, emerge as products.
authors.affiliation: Celltech Research Division, Celltech Ltd, Slough Berks, U.K.
authors.forename: J R
authors.initials: JR
authors.lastname: Adair
mesh_terms: D000818:Animals; D000906:Antibodies / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity; D002478:Cells, Cultured; D003165:Complement System Proteins / Q000276:immunology; D004926:Escherichia coli; D006801:Humans; D051379:Mice; D015202:Protein Engineering; D016719:Radioimmunodetection; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012441:Saccharomyces cerevisiae
chemical_list: D000906:Antibodies; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins; D003165:Complement System Proteins